Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer's disease pathology.

[1]  W. Markesbery,et al.  Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression , 2012, Neurobiology of Aging.

[2]  Douglas Galasko,et al.  Increased Cerebrospinal Fluid F2-Isoprostanes are Associated with Aging and Latent Alzheimer’s Disease as Identified by Biomarkers , 2011, NeuroMolecular Medicine.

[3]  G. Logroscino,et al.  Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option? , 2011, Expert opinion on investigational drugs.

[4]  F. Calon,et al.  Docosahexaenoic Acid-Derived Neuroprotectin D1 Induces Neuronal Survival via Secretase- and PPARγ-Mediated Mechanisms in Alzheimer's Disease Models , 2011, PloS one.

[5]  F. Panza,et al.  PLASMA LIPID DISTURBANCES AND COGNITIVE DECLINE , 2010, Journal of the American Geriatrics Society.

[6]  Eoin Fahy,et al.  Lipidomics reveals a remarkable diversity of lipids in human plasma1[S] , 2010, Journal of Lipid Research.

[7]  A. A. Farooqui.  Hot Topics in Neural Membrane Lipidology , 2010 .

[8]  A. A. Farooqui.  Neurochemical Aspects of Neurotraumatic and Neurodegenerative Diseases , 2010 .

[9]  T. Oster,et al.  Docosahexaenoic acid and synaptic protection in Alzheimer's disease mice. , 2010, Biochimica et biophysica acta.

[10]  D. Praticò.  The neurobiology of isoprostanes and Alzheimer's disease. , 2010, Biochimica et biophysica acta.

[11]  A. A. Farooqui,et al.  Lipid mediators in the nucleus: Their potential contribution to Alzheimer's disease. , 2010, Biochimica et biophysica acta.

[12]  P. Foley.  Lipids in Alzheimer's disease: A century-old story. , 2010, Biochimica et biophysica acta.

[13]  D. Butterfield,et al.  Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. , 2010, Biochimica et biophysica acta.

[14]  R. Koehler,et al.  Cytosolic phospholipase A2 alpha amplifies early cyclooxygenase-2 expression, oxidative stress and MAP kinase phosphorylation after cerebral ischemia in mice , 2010, Journal of Neuroinflammation.

[15]  J. Aoki,et al.  Biological roles of lysophosphatidic acid signaling through its production by autotaxin. , 2010, Biochimie.

[16]  C. Ramassamy,et al.  Potential role of acrolein in neurodegeneration and in Alzheimer's disease. , 2010, Current molecular pharmacology.

[17]  L. Roberts,et al.  Isoketals form cytotoxic phosphatidylethanolamine adducts in cells , 2010, Journal of Lipid Research.

[18]  Y. Yamamoto,et al.  Platelet-activating factor-induced synaptic facilitation is associated with increased calcium/calmodulin-dependent protein kinase II, protein kinase C and extracellular signal-regulated kinase activities in the rat hippocampal CA1 region , 2010, Neuroscience.

[19]  F. Panza,et al.  Frontiers in Aging Neuroscience Aging Neuroscience Review Article Brain Inflammation in Alzheimer's Disease , 2022 .

[20]  J. Mamo,et al.  Dietary fats, cerebrovasculature integrity and Alzheimer's disease risk. , 2010, Progress in lipid research.

[21]  B. Strooper.  Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process , 2010 .

[22]  G. Jicha,et al.  Omega-3 fatty acids: potential role in the management of early Alzheimer’s disease , 2010, Clinical interventions in aging.

[23]  V. Nardicchi,et al.  Low Molecular Weight Phospholipases A2 in Mammalian Brain and Neural Cells: Roles in Functions and Dysfunctions , 2010, Molecular Neurobiology.

[24]  Á. Almeida,et al.  Group IIA secretory phospholipase A2 (GIIA) mediates apoptotic death during NMDA receptor activation in rat primary cortical neurons , 2010, Journal of neurochemistry.

[25]  C. Gong,et al.  Deregulation of sphingolipid metabolism in Alzheimer's disease , 2010, Neurobiology of Aging.

[26]  B. Liu,et al.  Expression of the apoptosis-related proteins caspase-3 and NF-κB in the hippocampus of Tg2576 mice , 2010, Neuroscience bulletin.

[27]  A. A. Farooqui.  Studies on Plasmalogen-Selective Phospholipase A2 in Brain , 2010, Molecular Neurobiology.

[28]  F. Panza,et al.  Towards Disease-Modifying Treatment of Alzheimers Disease: Drugs Targeting β -Amyloid , 2009 .

[29]  David S. Park,et al.  Amyloid-β42 signals tau hyperphosphorylation and compromises neuronal viability by disrupting alkylacylglycerophosphocholine metabolism , 2009, Proceedings of the National Academy of Sciences.

[30]  J. Duggan,et al.  Alzheimer's disease and retinal neurodegeneration. , 2009, Current Alzheimer research.

[31]  J. Lah,et al.  DHA diet reduces AD pathology in young APPswe/PS1ΔE9 transgenic mice: Possible gender effects , 2009, Journal of neuroscience research.

[32]  R. Bazinet.  Is the brain arachidonic acid cascade a common target of drugs used to manage bipolar disorder? , 2009, Biochemical Society transactions.

[33]  M. Setou,et al.  Visualization of the cell-selective distribution of PUFA-containing phosphatidylcholines in mouse brain by imaging mass spectrometry[S] , 2009, Journal of Lipid Research.

[34]  P. Barberger-Gateau,et al.  Fish, docosahexaenoic acid and Alzheimer's disease. , 2009, Progress in lipid research.

[35]  N. Bazan.  Cellular and molecular events mediated by docosahexaenoic acid-derived neuroprotectin D1 signaling in photoreceptor cell survival and brain protection. , 2009, Prostaglandins, leukotrienes, and essential fatty acids.

[36]  A. A. Farooqui.  Beneficial Effects of Fish Oil on Human Brain , 2009 .

[37]  S. Haneuse,et al.  Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort , 2009, Neurology.

[38]  M. Memo,et al.  Redox proteomics identification of 4‐hydroxynonenal‐modified brain proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease pathogenesis , 2009, Proteomics. Clinical applications.

[39]  James T Becker,et al.  Mild cognitive impairment and alzheimer disease: patterns of altered cerebral blood flow at MR imaging. , 2009, Radiology.

[40]  R. Anwyl.  Metabotropic glutamate receptor-dependent long-term potentiation , 2009, Neuropharmacology.

[41]  C. Serhan,et al.  Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions , 2009, The Journal of experimental medicine.

[42]  S. DeKosky,et al.  Increased 5-Lipoxygenase Immunoreactivity in the Hippocampus of Patients With Alzheimer's Disease , 2008, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[43]  R. Bazinet,et al.  Regulation of brain polyunsaturated fatty acid uptake and turnover. , 2008, Prostaglandins, leukotrienes, and essential fatty acids.

[44]  T. Montine,et al.  Therapeutic targets in prostaglandin E2 signaling for neurologic disease. , 2008, Current medicinal chemistry.

[45]  Seth Love,et al.  Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.

[46]  R. Green,et al.  Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. , 2008, Archives of neurology.

[47]  A. Simopoulos,et al.  The Importance of the Omega-6/Omega-3 Fatty Acid Ratio in Cardiovascular Disease and Other Chronic Diseases , 2008, Experimental biology and medicine.

[48]  K. Mackie,et al.  Wiring and firing neuronal networks: endocannabinoids take center stage , 2008, Current Opinion in Neurobiology.

[49]  Charles N. Serhan,et al.  Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators , 2008, Nature Reviews Immunology.

[50]  M. Caplan,et al.  Polyunsaturated fatty acids block platelet-activating factor-induced phosphatidylinositol 3 kinase/Akt-mediated apoptosis in intestinal epithelial cells. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[51]  R. Veerhuis,et al.  Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology. , 2008, Current pharmaceutical design.

[52]  Bin Zhang,et al.  Thromboxane Receptor Activation Mediates Isoprostane-Induced Increases in Amyloid Pathology in Tg2576 Mice , 2008, The Journal of Neuroscience.

[53]  W. Gattaz,et al.  Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme , 2008, Psychopharmacology.

[54]  G. Poli,et al.  4-Hydroxynonenal-protein adducts: A reliable biomarker of lipid oxidation in liver diseases. , 2008, Molecular aspects of medicine.

[55]  H. Raza,et al.  Alterations in mitochondrial respiratory functions, redox metabolism and apoptosis by oxidant 4-hydroxynonenal and antioxidants curcumin and melatonin in PC12 cells. , 2008, Toxicology and applied pharmacology.

[56]  Dermot F. Reilly,et al.  Neurofurans, Novel Indices of Oxidant Stress Derived from Docosahexaenoic Acid* , 2008, Journal of Biological Chemistry.

[57]  N. Mons,et al.  Retinoid Hyposignaling Contributes to Aging-Related Decline in Hippocampal Function in Short-Term/Working Memory Organization and Long-Term Declarative Memory Encoding in Mice , 2008, The Journal of Neuroscience.

[58]  H. Mount,et al.  The low density lipoprotein receptor is not necessary for maintaining mouse brain polyunsaturated fatty acid concentrations Published, JLR Papers in Press, October 11, 2007. , 2008, Journal of Lipid Research.

[59]  M. Tafti,et al.  Functional implication of the vitamin A signaling pathway in the brain. , 2007, Archives of neurology.

[60]  L. Horrocks,et al.  Comparison of biochemical effects of statins and fish oil in brain: The battle of the titans , 2007, Brain Research Reviews.

[61]  F. Calderon,et al.  Role of RXR in neurite outgrowth induced by docosahexaenoic acid. , 2007, Prostaglandins, leukotrienes, and essential fatty acids.

[62]  S. Rapoport,et al.  Brain metabolism of nutritionally essential polyunsaturated fatty acids depends on both the diet and the liver. , 2007, Prostaglandins, leukotrienes, and essential fatty acids.

[63]  D. Butterfield,et al.  Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment , 2007 .

[64]  Mitsuru Sato,et al.  Lysophosphatidylcholine potentiates Ca2+ influx, pore formation and p44/42 MAP kinase phosphorylation mediated by P2X7 receptor activation in mouse microglial cells , 2007, Journal of neurochemistry.

[65]  P. Zandi,et al.  Does NSAID use modify cognitive trajectories in the elderly? , 2007, Neurology.

[66]  J. Hanoune.  Handbook of Neurochemistry and Molecular Neurobiology: Behavioral Neurochemistry, Neuroendocrinology and Molecular Neurobiology , 2007 .

[67]  L. Horrocks,et al.  Interactions between neural membrane glycerophospholipid and sphingolipid mediators: A recipe for neural cell survival or suicide , 2007, Journal of neuroscience research.

[68]  Kathryn Ziegler-Graham,et al.  Forecasting the global burden of Alzheimer’s disease , 2007, Alzheimer's & Dementia.

[69]  R. Green,et al.  Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial , 2007, Neurology.

[70]  C. Serhan,et al.  Resolvins and protectins in the termination program of acute inflammation. , 2007, Trends in immunology.

[71]  P. Heusler,et al.  Platelet-activating factor contributes to the induction of long-term potentiation in the rat somatosensory cortex in vitro , 2007, Brain Research.

[72]  Michael T. Heneka,et al.  Inflammatory processes in Alzheimer's disease , 2007, Journal of Neuroimmunology.

[73]  P. Montuschi,et al.  Insights into oxidative stress: the isoprostanes. , 2007, Current medicinal chemistry.

[74]  D. Aslan,et al.  Determination of malondialdehyde, reduced glutathione levels and APOE4 allele frequency in late-onset Alzheimer's disease in Denizli, Turkey. , 2007, Clinical biochemistry.

[75]  A. Goodman.  Retinoid receptors, transporters, and metabolizers as therapeutic targets in late onset Alzheimer disease , 2006, Journal of cellular physiology.

[76]  S. Rapoport,et al.  Brain elongation of linoleic acid is a negligible source of the arachidonate in brain phospholipids of adult rats. , 2006, Biochimica et biophysica acta.

[77]  J. Phillis,et al.  Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: Their role and involvement in neurological disorders , 2006, Brain Research Reviews.

[78]  A. A. Farooqui,et al.  Effects of intracerebroventricular injections of free fatty acids, lysophospholipids, or platelet activating factor in a mouse model of orofacial pain , 2006, Experimental Brain Research.

[79]  Lisa Chang,et al.  Chronic Lithium Chloride Administration Attenuates Brain NMDA Receptor-Initiated Signaling via Arachidonic Acid in Unanesthetized Rats , 2006, Neuropsychopharmacology.

[80]  G. Cole,et al.  Docosahexaenoic Acid Protects from Amyloid and Dendritic Pathology in an Alzheimer's Disease Mouse Model , 2006, Nutrition and health.

[81]  P. Raina,et al.  Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. , 2006, The American journal of medicine.

[82]  B. Kriem,et al.  Soluble oligomers of amyloid-β peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway , 2006, Neurobiology of Disease.

[83]  H. Kanazawa,et al.  Increased F2-Isoprostane Levels in the Rat Brain and Plasma Caused by Oxidative Stress and Aging, and Inhibitory Effect of Vitamin E , 2006 .

[84]  J. Cui,et al.  Hypoxia-sensitive domain in the human cytosolic phospholipase A2 promoter , 2006, Neuroreport.

[85]  J. Bonventre,et al.  Release of Free F2-isoprostanes from Esterified Phospholipids Is Catalyzed by Intracellular and Plasma Platelet-activating Factor Acetylhydrolases* , 2006, Journal of Biological Chemistry.

[86]  S. M. Cowsik,et al.  Neuroprotective Role of Neurokinin B (NKB) on β-amyloid (25–35) Induced Toxicity in Aging Rat Brain Synaptosomes: Involvement in Oxidative Stress and Excitotoxicity , 2006, Biogerontology.

[87]  Gang Wang,et al.  Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity , 2006, Nature Medicine.

[88]  W. Roberts,et al.  The Editor's roundtable: cyclooxygenase-2 inhibitors and cardiovascular risk. , 2005, The American journal of cardiology.

[89]  John Savill,et al.  Resolution of inflammation: the beginning programs the end , 2005, Nature Immunology.

[90]  S. Doré,et al.  Stimulation of PGE2 receptors EP2 and EP4 protects cultured neurons against oxidative stress and cell death following β‐amyloid exposure , 2005 .

[91]  M. Beal,et al.  Are mitochondria critical in the pathogenesis of Alzheimer's disease? , 2005, Brain Research Reviews.

[92]  Charles N Serhan,et al.  A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. , 2005, The Journal of clinical investigation.

[93]  J. Morrow,et al.  Recent advances in the biochemistry and clinical relevance of the isoprostane pathway , 2005, Lipids.

[94]  E. Ponomarev,et al.  Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli , 2005, Journal of neurochemistry.

[95]  N. Bazan.  Lipid signaling in neural plasticity, brain repair, and neuroprotection , 2005, Molecular Neurobiology.

[96]  Y. Hannun,et al.  The Coordination of Prostaglandin E2 Production by Sphingosine-1-phosphate and Ceramide-1-phosphate , 2005, Molecular Pharmacology.

[97]  J. Morrow,et al.  Regiochemistry of Neuroprostanes Generated from the Peroxidation of Docosahexaenoic Acid in Vitro and in Vivo* , 2005, Journal of Biological Chemistry.

[98]  Yi-Sook Jung,et al.  Arachidonic acid induces neuronal death through lipoxygenase and cytochrome P450 rather than cyclooxygenase , 2005, Journal of neuroscience research.

[99]  E. Fedele,et al.  Cyclo‐oxygenase‐1 and ‐2 differently contribute to prostaglandin E2 synthesis and lipid peroxidation after in vivo activation of N‐methyl‐d‐aspartate receptors in rat hippocampus , 2005, Journal of neurochemistry.

[100]  M. O’Banion,et al.  The role of COX-1 and COX-2 in Alzheimer's disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs. , 2005, Current drug targets. CNS and neurological disorders.

[101]  M. Mattson,et al.  Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia , 2005, Annals of neurology.

[102]  V. Pallet,et al.  Differential effect of retinoic acid and triiodothyronine on the age-related hypo-expression of neurogranin in rat , 2005, Neurobiology of Aging.

[103]  T. Montine,et al.  Microglia Lacking E Prostanoid Receptor Subtype 2 Have Enhanced Aβ Phagocytosis yet Lack Aβ-Activated Neurotoxicity , 2005 .

[104]  N. Bazan.  Neuroprotectin D1 (NPD1): A DHA‐Derived Mediator that Protects Brain and Retina Against Cell Injury‐Induced Oxidative Stress , 2005, Brain pathology.

[105]  O. Boutaud,et al.  Cyclooxygenase‐Dependent Lipid‐Modification of Brain Proteins , 2005, Brain pathology.

[106]  J. Fessel,et al.  The Biochemistry of the Isoprostane, Neuroprostane, and Isofuran Pathways of Lipid Peroxidation , 2005, Chemistry and physics of lipids.

[107]  Stanley I. Rapoport,et al.  D2 but not D1 dopamine receptor stimulation augments brain signaling involving arachidonic acid in unanesthetized rats , 2005, Psychopharmacology.

[108]  M. L. de Ceballos,et al.  Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation , 2005, The Journal of Neuroscience.

[109]  R. Shi,et al.  Acrolein induces oxidative stress in brain mitochondria , 2005, Neurochemistry International.

[110]  T. Lanz,et al.  Lack of Specific Amyloid-β(1-42) Suppression by Nonsteroidal Anti-Inflammatory Drugs in Young, Plaque-Free Tg2576 Mice and in Guinea Pig Neuronal Cultures , 2005, Journal of Pharmacology and Experimental Therapeutics.

[111]  B. Kriem,et al.  Cytosolic phospholipase A2 mediates neuronal apoptosis induced by soluble oligomers of the amyloid‐β peptide , 2005 .

[112]  Carola Hunte,et al.  Lipids in membrane protein structures. , 2004, Biochimica et biophysica acta.

[113]  A. A. Farooqui,et al.  Intracerebroventricular injection of phospholipases A2 inhibitors modulates allodynia after facial carrageenan injection in mice , 2004, Pain.

[114]  Charles N. Serhan,et al.  Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers , 2004, Lipids.

[115]  J. Chun,et al.  Cell surface receptors in lysophospholipid signaling. , 2004, Seminars in cell & developmental biology.

[116]  L. Minghetti,et al.  Isoprostanes as biomarkers and mediators of oxidative injury in infant and adult central nervous system diseases. , 2004, Current neurovascular research.

[117]  Q. Wang,et al.  PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis , 2004, Annals of neurology.

[118]  B. Giepmans,et al.  The ins and outs of lysophosphatidic acid signaling , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[119]  T. Willson,et al.  Polyunsaturated Fatty Acids Including Docosahexaenoic and Arachidonic Acid Bind to the Retinoid X Receptor α Ligand-binding Domain* , 2004, Molecular & Cellular Proteomics.

[120]  F. Lehmann,et al.  Physiological mechanisms of lysophosphatidylcholine‐induced de‐ramification of murine microglia , 2004, The Journal of physiology.

[121]  D. Roden,et al.  Modification of Proteins by Isoketal-containing Oxidized Phospholipids* , 2004, Journal of Biological Chemistry.

[122]  L. Horrocks,et al.  Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function. , 2004, Prostaglandins, leukotrienes, and essential fatty acids.

[123]  C. Leslie,et al.  Ceramide 1-Phosphate Is a Direct Activator of Cytosolic Phospholipase A2* , 2004, Journal of Biological Chemistry.

[124]  J. Fessel,et al.  The biochemistry of the isoprostane, neuroprostane, and isofuran Pathways of lipid peroxidation. , 2004, Brain pathology.

[125]  L. Roberts,et al.  Isoketals: highly reactive ?-ketoaldehydes formed from the H 2-isoprostane pathway , 2004 .

[126]  A. Schwab,et al.  Functional importance of Ca2+‐activated K+ channels for lysophosphatidic acid‐induced microglial migration , 2004, The European journal of neuroscience.

[127]  D. Butterfield,et al.  4-Hydroxynonenal oxidatively modifies histones: implications for Alzheimer's disease , 2004, Neuroscience Letters.

[128]  M. Mattson,et al.  Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[129]  Á. Simonyi,et al.  Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. , 2004, Journal of lipid research.

[130]  S. Basu.  ReviewIsoprostanes: Novel Bioactive Products of Lipid Peroxidation , 2004, Free radical research.

[131]  M. Vacca,et al.  Aging increases amyloid β-peptide-induced 8-iso-prostaglandin F2α release from rat brain , 2004, Neurobiology of Aging.

[132]  K. Ishii,et al.  The LPS receptor (CD14) links innate immunity with Alzheimer's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[133]  J. Shioi,et al.  Cyclooxygenase (COX)-2 and COX-1 Potentiate β-Amyloid Peptide Generation through Mechanisms That Involve γ-Secretase Activity* , 2003, Journal of Biological Chemistry.

[134]  Alberto Rábano,et al.  Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains , 2003, The Journal of Neuroscience.

[135]  C. Woolf,et al.  Central sensitization and LTP: do pain and memory share similar mechanisms? , 2003, Trends in Neurosciences.

[136]  Song‐Pyo Hong,et al.  Novel Docosanoids Inhibit Brain Ischemia-Reperfusion-mediated Leukocyte Infiltration and Pro-inflammatory Gene Expression* , 2003, Journal of Biological Chemistry.

[137]  M. Eder,et al.  CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity , 2003, Science.

[138]  S. Tonstad,et al.  8-isoprostane increases expression of interleukin-8 in human macrophages through activation of mitogen-activated protein kinases. , 2003, Cardiovascular research.

[139]  J. Morrow,et al.  The isoprostanes: unique products of arachidonic acid oxidation-a review. , 2003, Current medicinal chemistry.

[140]  S. Weggen,et al.  Evidence That Nonsteroidal Anti-inflammatory Drugs Decrease Amyloid β42 Production by Direct Modulation of γ-Secretase Activity* , 2003, Journal of Biological Chemistry.

[141]  P. Scheltens,et al.  Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer’s disease , 2003, Journal of Neural Transmission.

[142]  R. Schaur,et al.  Basic aspects of the biochemical reactivity of 4-hydroxynonenal. , 2003, Molecular aspects of medicine.

[143]  B. Penke,et al.  Neuroprotective effect of developmental docosahexaenoic acid supplement against excitotoxic brain damage in infant rats , 2003, Neuroscience.

[144]  G. Reiser,et al.  Docosahexaenoic acid and arachidonic acid release in rat brain astrocytes is mediated by two separate isoforms of phospholipase A2 and is differently regulated by cyclic AMP and Ca2+ , 2003, British journal of pharmacology.

[145]  K. Uchida,et al.  4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. , 2003, Progress in lipid research.

[146]  J. Bell,et al.  Chronic lithium administration potentiates brain arachidonic acid signaling at rest and during cholinergic activation in awake rats , 2003, Journal of neurochemistry.

[147]  S. Powell,et al.  Isofurans, but not F2‐isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease , 2003, Journal of neurochemistry.

[148]  C. Serhan,et al.  Novel Docosatrienes and 17S-Resolvins Generated from Docosahexaenoic Acid in Murine Brain, Human Blood, and Glial Cells , 2003, The Journal of Biological Chemistry.

[149]  A. Pardee,et al.  Evidence for defective retinoid transport and function in late onset Alzheimer's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[150]  T. Montine,et al.  Mercapturate Metabolism of 4‐Hydroxy‐2‐Nonenal ien Rat and Human Cerebrum , 2003, Journal of neuropathology and experimental neurology.

[151]  Andrea Balbo,et al.  Imaging Brain Phospholipase A2 Activation in Awake Rats in Response to the 5-HT2A/2C Agonist (±)2,5-Dimethoxy-4-Iodophenyl-2-Aminopropane (DOI) , 2003, Neuropsychopharmacology.

[152]  J. Fessel,et al.  Discovery of lipid peroxidation products formed in vivo with a substituted tetrahydrofuran ring (isofurans) that are favored by increased oxygen tension , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[153]  J. Chun,et al.  Lysophosphatidic acid in neural signaling. , 2002, Neuroreport.

[154]  A. Simopoulos.  Omega-3 Fatty Acids in Inflammation and Autoimmune Diseases , 2002, Journal of the American College of Nutrition.

[155]  M. Ball,et al.  Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: Transcription and neurotrophic factor down‐regulation and up‐regulation of apoptotic and pro‐inflammatory signaling , 2002, Journal of neuroscience research.

[156]  G. Perry,et al.  Book Review: Is Alzheimer’s Disease a Mitochondrial Disorder? , 2002, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[157]  T. Montine,et al.  Prostaglandin H2 (PGH2) accelerates formation of amyloid β1−42 oligomers , 2002, Journal of neurochemistry.

[158]  N. Bazan,et al.  Prostaglandins and other lipid mediators in Alzheimer's disease. , 2002, Prostaglandins & other lipid mediators.

[159]  Rajnish A. Gupta,et al.  15-Lipoxygenase Metabolism of 2-Arachidonylglycerol , 2002, The Journal of Biological Chemistry.

[160]  K. Meier,et al.  Lysophosphatidic acid as an autocrine and paracrine mediator. , 2002, Biochimica et biophysica acta.

[161]  J. Ávila,et al.  Regulation of neuronal cytoskeleton by lysophosphatidic acid: role of GSK-3. , 2002, Biochimica et biophysica acta.

[162]  D. Borchelt,et al.  Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer’s Disease neuropathology , 2002, Neurobiology of Aging.

[163]  D. Coppola,et al.  Microglial Activation and β-Amyloid Deposit Reduction Caused by a Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drug in Amyloid Precursor Protein Plus Presenilin-1 Transgenic Mice , 2002, The Journal of Neuroscience.

[164]  T. Hamazaki,et al.  Suppression of platelet-activating factor generation and modulation of arachidonate metabolism by dietary enrichment with (n-9) eicosatrienoic acid or docosahexaenoic acid in mouse peritoneal cells. , 2001, Prostaglandins & other lipid mediators.

[165]  T. Montine,et al.  Formation of Highly Reactive γ-Ketoaldehydes (Neuroketals) as Products of the Neuroprostane Pathway* , 2001, The Journal of Biological Chemistry.

[166]  R. Jaffard,et al.  Alleviation of a Selective Age-Related Relational Memory Deficit in Mice by Pharmacologically Induced Normalization of Brain Retinoid Signaling , 2001, The Journal of Neuroscience.

[167]  A. Nunomura,et al.  Oxidative Damage Is the Earliest Event in Alzheimer Disease , 2001, Journal of neuropathology and experimental neurology.

[168]  J. Pettegrew,et al.  Brain Membrane Phospholipid Alterations in Alzheimer's Disease , 2001, Neurochemical Research.

[169]  Virginia M. Y. Lee,et al.  Increased Lipid Peroxidation Precedes Amyloid Plaque Formation in an Animal Model of Alzheimer Amyloidosis , 2001, The Journal of Neuroscience.

[170]  N. Nishiyama,et al.  Phospholipase A2 mediates ischemic injury in the hippocampus: a regional difference of neuronal vulnerability , 2001, The European journal of neuroscience.

[171]  L. Janssen.  Isoprostanes: an overview and putative roles in pulmonary pathophysiology. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[172]  Xianlin Han,et al.  Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry , 2001, Journal of neurochemistry.

[173]  S. Heishman,et al.  Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. , 2001, Archives of general psychiatry.

[174]  J. Dietschy,et al.  Cholesterol metabolism in the brain , 2001, Current opinion in lipidology.

[175]  T. Montine,et al.  Acrolein inhibits respiration in isolated brain mitochondria. , 2001, Biochimica et biophysica acta.

[176]  M. Ross,et al.  Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[177]  L. Marnett,et al.  Selective oxygenation of the endocannabinoid 2-arachidonylglycerol by leukocyte-type 12-lipoxygenase. , 2001, Biochemistry.

[178]  T. Perlmann,et al.  Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. , 2000, Science.

[179]  W. Markesbery,et al.  Acrolein, a product of lipid peroxidation, inhibits glucose and glutamate uptake in primary neuronal cultures. , 2000, Free radical biology & medicine.

[180]  G. Poli,et al.  4‐Hydroxynonenal in the Pathomechanisms of Oxidative Stress , 2000, IUBMB life.

[181]  L. Horrocks,et al.  Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders. , 2000, Chemistry and physics of lipids.

[182]  G. Goracci,et al.  Properties and Regulation of Microsomal PAF-Synthesizing Enzymes in Rat Brain Cortex , 2000, Neurochemical Research.

[183]  T. Uliasz,et al.  Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. , 2000, The Journal of pharmacology and experimental therapeutics.

[184]  K. Olden,et al.  Arachidonic Acid Activates Mitogen-activated Protein (MAP) Kinase-activated Protein Kinase 2 and Mediates Adhesion of a Human Breast Carcinoma Cell Line to Collagen Type IV through a p38 MAP Kinase-dependent Pathway* , 2000, The Journal of Biological Chemistry.

[185]  J. Morrow.  THE ISOPROSTANES: THEIR QUANTIFICATION AS AN INDEX OF OXIDANT STRESS STATUS IN VIVO† , 2000, Drug metabolism reviews.

[186]  Claire Shepherd,et al.  Alzheimer’s Disease And Inflammation: A Review Of Cellular And Therapeutic Mechanisms , 2000, Clinical and experimental pharmacology & physiology.

[187]  F. Wandosell,et al.  The Neurite Retraction Induced by Lysophosphatidic Acid Increases Alzheimer's Disease-like Tau Phosphorylation* , 1999, The Journal of Biological Chemistry.

[188]  M. Moskowitz,et al.  MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[189]  D. Stephenson,et al.  Cytosolic phospholipase A2 is induced in reactive glia following different forms of neurodegeneration , 1999, Glia.

[190]  P. Lantos,et al.  Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. , 1999, Journal of neuropathology and experimental neurology.

[191]  Georg W. Kreutzberg,et al.  Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function , 1999, Brain Research Reviews.

[192]  T. Montine,et al.  4‐Hydroxy‐2(E)‐Nonenal Inhibits CNS Mitochondrial Respiration at Multiple Sites , 1999, Journal of neurochemistry.

[193]  R. Davis,et al.  Glutamate Receptor Signaling Interplay Modulates Stress-sensitive Mitogen-activated Protein Kinases and Neuronal Cell Death* , 1999, The Journal of Biological Chemistry.

[194]  P. May,et al.  Characterization of 8‐Epiprostaglandin F2α as aMarker of Amyloid β‐Peptide‐Induced Oxidative Damage , 1999 .

[195]  G. Gibson,et al.  Protein‐Bound Acrolein , 1999, Journal of neurochemistry.

[196]  G. Ramakers,et al.  Regulation of astrocyte morphology by RhoA and lysophosphatidic acid. , 1998, Experimental cell research.

[197]  J. Kanfer,et al.  Phospholipases as mediators of amyloid beta peptide neurotoxicity: an early event contributing to neurodegeneration characteristic of Alzheimer's disease , 1998, Neuroscience Letters.

[198]  N. Bazan,et al.  Recombinant plasma‐type platelet‐activating factor acetylhydrolase attenuates NMDA‐induced hippocampal neuronal apoptosis , 1998, Journal of neuroscience research.

[199]  T. Montine,et al.  Cerebrospinal fluid F2‐isoprostane levels are increased in Alzheimer's disease , 1998, Annals of neurology.

[200]  P. Aisen,et al.  Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain , 1998, Neuroscience.

[201]  T. Montine,et al.  Formation of Isoprostane-like Compounds (Neuroprostanes) in Vivo from Docosahexaenoic Acid* , 1998, The Journal of Biological Chemistry.

[202]  S. Basu,et al.  Metabolism of 8‐iso‐prostaglandin F2α , 1998 .

[203]  J. Morrow,et al.  A novel mechanism for vasoconstrictor action of 8-isoprostaglandin F2α on retinal vessels. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.

[204]  W. D. Ehmann,et al.  Elevated 4-Hydroxynonenal in Ventricular Fluid in Alzheimer’s Disease , 1997, Neurobiology of Aging.

[205]  E. Stadtman,et al.  Protein Oxidation in Aging, Disease, and Oxidative Stress* , 1997, The Journal of Biological Chemistry.

[206]  Y. Hannun,et al.  Phospholipase A2 Is Necessary for Tumor Necrosis Factor α-induced Ceramide Generation in L929 Cells* , 1997, The Journal of Biological Chemistry.

[207]  M. Mattson,et al.  Lysophosphatidic Acid Induces a Sustained Elevation of Neuronal Intracellular Calcium , 1997, Journal of neurochemistry.

[208]  G. Poirier,et al.  Involvement of caspase-dependent activation of cytosolic phospholipase A2 in tumor necrosis factor-induced apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[209]  Y. Hirashima,et al.  Involvement of platelet-activating factor (PAF) in glutamate neurotoxicity in rat neuronal cultures , 1997, Brain Research.

[210]  Stanley I. Rapoport,et al.  Membrane Phospholipid Alterations In Alzheimer's Disease: Deficiency of Ethanolamine Plasmalogens , 1997, Neurochemical Research.

[211]  L. Rubin,et al.  Lysophosphatidic Acid Increases Tight Junction Permeability in Cultured Brain Endothelial Cells , 1997, Journal of neurochemistry.

[212]  R. Faull,et al.  Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain , 1997, Neuroscience.

[213]  J. Phillis,et al.  Mechanisms of glutamate and aspartate release in the ischemic rat cerebral cortex , 1996, Brain Research.

[214]  Takao Shimizu,et al.  Predominant Expression of Platelet-Activating Factor Receptor in the Rat Brain Microglia , 1996, The Journal of Neuroscience.

[215]  B. Yu,et al.  4-Hydroxyhexenal Is a Potent Inducer of the Mitochondrial Permeability Transition (*) , 1996, The Journal of Biological Chemistry.

[216]  R. Miledi,et al.  Lysophosphatidic Acid‐Induced Neurite Retraction in PC12 Cells: Neurite‐Protective Effects of Cyclic AMP Signaling , 1996, Journal of neurochemistry.

[217]  R. Miledi,et al.  Lysophosphatidic Acid‐Induced Neurite Retraction in PC12 Cells: Control by Phosphoinositide‐Ca2+ Signaling and Rho , 1996, Journal of neurochemistry.

[218]  D. Selkoe,et al.  Cytosolic Phospholipase A2(cPLA2) Immunoreactivity Is Elevated in Alzheimer's Disease Brain , 1996, Neurobiology of Disease.

[219]  L. Horrocks,et al.  Neural membrane phospholipids in alzheimer disease , 1995, Neurochemical Research.

[220]  K. Wu,et al.  Transcriptional Induction of Endothelial Nitric Oxide Synthase Type III by Lysophosphatidylcholine (*) , 1995, The Journal of Biological Chemistry.

[221]  I. Izquierdo,et al.  Memory enhancement by intrahippocampal, intraamygdala, or intraentorhinal infusion of platelet-activating factor measured in an inhibitory avoidance task. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[222]  G. Tigyi,et al.  Lysophosphatidic acid alters cerebrovascular reactivity in piglets. , 1995, The American journal of physiology.

[223]  G. Kreutzberg,et al.  Microglia: Intrinsic immuneffector cell of the brain , 1995, Brain Research Reviews.

[224]  S. Swindells,et al.  Platelet-activating factor: a candidate human immunodeficiency virus type 1-induced neurotoxin , 1994, Journal of virology.

[225]  Kunio Kato,et al.  Platelet-activating factor as a potential retrograde messenger in CA1 hippocampal long-term potentiation , 1994, Nature.

[226]  Carol A. Barnes,et al.  Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids , 1993, Neuron.

[227]  J. Morrow,et al.  Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[228]  G. Goracci,et al.  Properties of PAF-synthesizing phosphocholinetransferase and evidence for lysoPAF acetyltransferase activity in rat brain , 1991, Lipids.

[229]  J. Growdon,et al.  Alterations of Phospholipid Metabolites in Postmortem Brain from Patients with Alzheimer's Disease a , 1991, Annals of the New York Academy of Sciences.

[230]  K. Kristensson,et al.  Fatty acid composition of brain phospholipids in aging and in Alzheimer’s disease , 1991, Lipids.

[231]  J. Hawthorne,et al.  Reduced Phosphoinositide Concentrations in Anterior Temporal Cortex of Alzheimer‐Diseased Brains , 1987, Journal of neurochemistry.

[232]  E. D. Mihelich,et al.  Stereochemical course of the autooxidative cyclization of lipid hydroperoxides to prostaglandin-like bicyclic endoperoxides , 1984 .

[233]  S. Rapoport,et al.  Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer's disease prefrontal cortex. , 2011, Journal of Alzheimer's disease : JAD.

[234]  B. Puig,et al.  Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex. , 2010, Journal of Alzheimer's disease : JAD.

[235]  A. A. Farooqui.  Neurochemical Aspects of Neurodegenerative Diseases , 2010 .

[236]  Stephan Bandelow,et al.  Visual impairment in Alzheimer's disease: a critical review. , 2010, Journal of Alzheimer's disease : JAD.

[237]  J. Malter,et al.  N-acetylcysteine prevents 4-hydroxynonenal- and amyloid-beta-induced modification and inactivation of neprilysin in SH-SY5Y cells. , 2010, Journal of Alzheimer's disease : JAD.

[238]  Alberto Pilotto,et al.  Nutraceutical properties of Mediterranean diet and cognitive decline: possible underlying mechanisms. , 2010, Journal of Alzheimer's disease : JAD.

[239]  A. A. Farooqui.  Perspective and Directions for Future Development on the Effects of Fish Oil Constituents on Brain , 2009 .

[240]  A. A. Farooqui.  Neural Membranes: A Pandora’s Box of Lipid Mediators , 2009 .

[241]  V. Nardicchi,et al.  13 Metabolism and Functions of Platelet-Activating Factor (PAF) in the Nervous Tissue , 2009 .

[242]  George Perry,et al.  Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. , 2009, Journal of Alzheimer's disease : JAD.

[243]  Rong Zhang,et al.  Altered cerebral hemodynamics in early Alzheimer disease: a pilot study using transcranial Doppler. , 2009, Journal of Alzheimer's disease : JAD.

[244]  L. Horrocks,et al.  Comprar Glycerophospholipids in the Brain · Phospholipases A2 in Neurological Disorders | Farooqui, Akhlaq A. | 9780387366029 | Springer , 2007 .

[245]  N. Bazan.  Synaptic signaling by lipids in the life and death of neurons , 2007, Molecular Neurobiology.

[246]  V. Marzo.  Endocannabinoids: synthesis and degradation. , 2006 .

[247]  J. Macdonald,et al.  Hippocampal long-term synaptic plasticity and signal amplification of NMDA receptors. , 2006, Critical reviews in neurobiology.

[248]  C. Serhan.  Novel omega -- 3-derived local mediators in anti-inflammation and resolution. , 2005, Pharmacology & therapeutics.

[249]  L. Horrocks,et al.  Plasmalogens, docosahexaenoic acid and neurological disorders. , 2003, Advances in experimental medicine and biology.

[250]  Nicolas G. Bazan,et al.  Synaptic lipid signaling: significance of polyunsaturated fatty acids and platelet-activating factor. , 2003, Journal of lipid research.

[251]  T. Montine,et al.  Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. , 2001, The American journal of pathology.

[252]  J. Magee,et al.  Attenuated LTP in hippocampal dentate gyrus neurons of mice deficient in the PAF receptor. , 2001, Journal of neurophysiology.

[253]  G. Zimmerman,et al.  Platelet-activating factor and related lipid mediators. , 2000, Annual review of biochemistry.

[254]  S. Ishii,et al.  Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. , 2000, Progress in lipid research.

[255]  J. Chun.  Lysophospholipid receptors: implications for neural signaling. , 1999, Critical reviews in neurobiology.

[256]  M. O’Banion,et al.  Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. , 1999, Critical reviews in neurobiology.

[257]  J. Vane,et al.  Cyclooxygenases 1 and 2. , 1998, Annual review of pharmacology and toxicology.

[258]  H. Esterbauer,et al.  Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. , 1991, Free radical biology & medicine.

[259]  L. Horrocks,et al.  Elevated Activities of Lipases and Lysophospholipase in Alzheimer's Disease , 1990 .

[260]  G. Porcellati.  Phospholipid Metabolism in Neural Membranes , 1983 .

[261]  M. Tabaton,et al.  Frontiers in Aging Neuroscience Aging Neuroscience Review Article Aβ and Oxidative Stress Oxidative Stress in Ad and Aging Oxidative Stress in Ad and Hypoxia Oxidative Stress in Ad and Hyperglycemia , 2022 .